Company
Trellis Bioscience
| Industry | clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases |
|---|
Funding raised
| Company | Round | Date |
|---|---|---|
| Trellis Bioscience | Series C | 2026-07-20 |
Company
| Industry | clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases |
|---|
| Company | Round | Date |
|---|---|---|
| Trellis Bioscience | Series C | 2026-07-20 |